XML 21 R10.htm IDEA: XBRL DOCUMENT
v3.10.0.1

Revenues | 9 Months Ended
--- | ---
Sep. 30, 2018
Revenue from Contract with Customer [Abstract] |
Revenues | Revenues Revenues by product and by geographic area We operate in one business segment: human therapeutics. Therefore, results of our operations are reported on a consolidated basis for purposes of segment reporting, consistent with internal management reporting. Revenues by product and by geographic area, based on customers’ locations, are presented below. Rest-of-world (ROW) revenues relate to products that are sold principally in Europe. Revenues were as follows (in millions):
|  | Three months ended September 30,
|  | 2018 |  | 2017
|  | US |  | ROW |  | Total |  | US |  | ROW |  | Total
Enbrel® |  | $ | 1,242 |  |  | $ | 50 |  |  | $ | 1,292 |  |  | $ | 1,309 |  |  | $ | 54 |  |  | $ | 1,363 |
Neulasta® |  | 897 |  |  | 154 |  |  | 1,051 |  |  | 977 |  |  | 146 |  |  | 1,123 |
Prolia® |  | 354 |  |  | 178 |  |  | 532 |  |  | 298 |  |  | 166 |  |  | 464 |
Aranesp® |  | 248 |  |  | 229 |  |  | 477 |  |  | 285 |  |  | 231 |  |  | 516 |
XGEVA® |  | 323 |  |  | 110 |  |  | 433 |  |  | 282 |  |  | 105 |  |  | 387 |
Sensipar® / Mimpara® |  | 330 |  |  | 79 |  |  | 409 |  |  | 373 |  |  | 84 |  |  | 457 |
EPOGEN® |  | 252 |  |  | — |  |  | 252 |  |  | 264 |  |  | — |  |  | 264 |
Other products |  | 614 |  |  | 450 |  |  | 1,064 |  |  | 509 |  |  | 370 |  |  | 879 |
Total product sales(1) |  | $ | 4,260 |  |  | $ | 1,250 |  |  | $ | 5,510 |  |  | $ | 4,297 |  |  | $ | 1,156 |  |  | $ | 5,453 |
Other revenues |  |  |  |  |  | 394 |  |  |  |  |  |  | 320 |
Total revenues(2) |  |  |  |  |  | $ | 5,904 |  |  |  |  |  |  | $ | 5,773 |
|  | Nine months ended September 30,
|  | 2018 |  | 2017
|  | US |  | ROW |  | Total |  | US |  | ROW |  | Total
Enbrel® |  | $ | 3,544 |  |  | $ | 155 |  |  | $ | 3,699 |  |  | $ | 3,838 |  |  | $ | 172 |  |  | $ | 4,010 |
Neulasta® |  | 2,854 |  |  | 452 |  |  | 3,306 |  |  | 2,962 |  |  | 458 |  |  | 3,420 |
Prolia® |  | 1,070 |  |  | 566 |  |  | 1,636 |  |  | 903 |  |  | 491 |  |  | 1,394 |
Aranesp® |  | 714 |  |  | 689 |  |  | 1,403 |  |  | 851 |  |  | 711 |  |  | 1,562 |
XGEVA® |  | 994 |  |  | 336 |  |  | 1,330 |  |  | 872 |  |  | 312 |  |  | 1,184 |
Sensipar® / Mimpara® |  | 1,069 |  |  | 257 |  |  | 1,326 |  |  | 1,052 |  |  | 253 |  |  | 1,305 |
EPOGEN® |  | 746 |  |  | — |  |  | 746 |  |  | 826 |  |  | — |  |  | 826 |
Other products |  | 1,783 |  |  | 1,303 |  |  | 3,086 |  |  | 1,474 |  |  | 1,051 |  |  | 2,525 |
Total product sales(1) |  | $ | 12,774 |  |  | $ | 3,758 |  |  | $ | 16,532 |  |  | $ | 12,778 |  |  | $ | 3,448 |  |  | $ | 16,226 |
Other revenues |  |  |  |  |  | 985 |  |  |  |  |  |  | 821 |
Total revenues(2) |  |  |  |  |  | $ | 17,517 |  |  |  |  |  |  | $ | 17,047 |
____________
(1) | Hedging gains and losses, which are included in product sales, were not material for the three and nine months ended September 30, 2018 and 2017.
(2) | Prior-period amounts are not adjusted under the modified-retrospective method of adoption.
Financing and payment Our payment terms vary by types and locations of customers and the products or services offered. Payment terms differ by jurisdiction and customer, but payment is generally required in a term ranging from 30 to 120 days from date of shipment or satisfaction of the performance obligation. For certain products or services and certain customer types, we may require payment before products are delivered or services are rendered to customers. Optional exemptions We do not disclose the value of unsatisfied performance obligations for (i) contracts with original expected lengths of one year or less or (ii) contracts for which we recognize revenue at the amount to which we have the right to invoice for the services performed.

X
- References No definition available. + Details
Name: | us-gaap_RevenueFromContractWithCustomerAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -URI http://asc.fasb.org/topic&trid=49130388 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -URI http://asc.fasb.org/topic&trid=2122369 + Details
Name: | us-gaap_RevenueFromContractWithCustomerTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration